The Catapult’s investment in solid-state NMR will provide technology previously been unavailable in the UK. In addition, advanced mass spectrometry and liquid handling in the facility will support advanced screening and target validation to identify future therapies for complex diseases.
Chris Molloy. CEO Medicines Discovery Catapult: Introducing Solid-state NMR, Mass Spectrometry and Acoustic Liquid Handling
Acoustic Liquid Handling